|Bid||4.2400 x 4000|
|Ask||4.2900 x 1200|
|Day's range||4.1100 - 5.2300|
|52-week range||2.4300 - 6.5000|
|Beta (5Y monthly)||2.55|
|PE ratio (TTM)||N/A|
|Earnings date||02 Mar 2022 - 07 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. So what A U.S. Court of Appeals for the Federal Circuit panel affirmed a previous ruling by the U.
What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) rocketed higher on Wednesday morning in response to a court ruling in its favor. The stock was up 70.2% at 11:41 a.m. on Wednesday. So what Moderna's (NASDAQ: MRNA) attempt to avoid paying royalties on the lipid nanoparticle (LNP) technology that its COVID vaccine relies upon took another turn for the worse.
WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (cHBV) infection and to treat coronaviruses (including COVID-19), today announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next gene